Similar Items: Simulation of long‐term lecanemab treatment effect on Alzheimer's disease progression
- Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
- Lecanemab treatment modulates brain volume and cerebrospinal fluid pathways in early Alzheimer's disease: Insights from longitudinal magnetic resonance imaging
- From clinical trial to clinical experience: Lecanemab therapy in a real‐world case series
- Real‐world use of lecanemab: patient pathway findings from a US multicenter study
- Polypharmacy is associated with lower progression from MCI to Alzheimer's disease, with sex‐specific patterns across drug classes
- Longitudinal changes in DTI‐ALPS and choroid plexus volume relative to CSF biomarkers during lecanemab treatment in mild cognitive impairment: A pilot study